Assessing and restoring adaptive immunity to HSV, VZV, and HHV-6 in solid organ and hematopoietic cell transplant recipients

Heldman, Madeleine R.; Aagaard, Kaja M.; Hill, Joshua A.

doi:10.1016/j.cmi.2022.02.001

Cited by 5 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Te manifestation of the herpes rash typically occurs in the dermatomes corresponding to the innervation of the nerves, primarily in the thoracic region, subsequently extending to the lumbar, cervical, cranial, and sacral regions. Noteworthy complications associated with this infection encompass postherpetic neuralgia, motor paralysis, and ocular herpes zoster [8][9][10]. Te infection typically presents with localized cutaneous symptoms; nevertheless, immunocompromised patients may exhibit involvement of internal organs and other secondary infections [11][12][13].…”

Section: Discussionmentioning

confidence: 99%

Enhancing Efficacy and Quality of Life in Patients with Herpes Zoster Infection in Hairy Cell Leukemia

Feng,

Tao,

et al. 2024

Case Reports in Hematology

View full text Add to dashboard Cite

Hairy cell leukemia (HCL) is an infrequent and persistent B-cell inert lymphoid leukemia. In this study, we present the case of a 71-year-old female patient with a previous diagnosis of variant HCL who experienced a severe herpes zoster infection leading to an extensive skin eruption. The patient’s initial diagnosis of HCL occurred 7 years ago, and she underwent treatment with cladribine, interferon, COP (cyclophosphamide, vincristine, and prednisone), benztropine tablets + clarithromycin dispersible, and ibrutinib. Immune disorders resulting from repeated prior chemotherapy and targeted therapy may potentially precipitate herpes zoster infection. Despite an initial two-week period of unresponsiveness to antivirals and nerve nutrition treatments, the introduction of topical Coptis liquid to the treatment regimen yielded significant efficacy. This case report underscores the potential of Chinese medicine as an adjunct to conventional antiviral therapy in the management of herpes zoster infection in immunocompromised patients. This treatment protocol has the potential to enhance efficacy, enhance quality of life, and serve as a more robust foundation for clinical diagnosis and improved treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Enhancing Efficacy and Quality of Life in Patients with Herpes Zoster Infection in Hairy Cell Leukemia

Feng,

Tao,

et al. 2024

Case Reports in Hematology

View full text Add to dashboard Cite

show abstract

VZV Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation in Children: When to Stop?

de Berranger,

Derache,

Ramdane

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

BackgroundAcyclovir treatment is an efficient prophylaxis to prevent varicella‐zoster virus (VZV) reactivation after allogeneic hematopoietic stem cell transplantation (HSCT).AimsThis single center retrospective study tried to determine if the lymphocytes immunophenotyping could help to determine the duration of prophylaxis, and evaluated complications, and associated risk factors for VZV infection.Methods and ResultsEighty‐four children underwent an allogeneic HSCT, in which 77 received an acyclovir prophylaxis. Twenty‐one of the 77 had a VZV infection with an incidence rate of 1.30 per 100 patients‐months (exact 95% CI, 0.81 to 2.01). Among these 21 patients with VZV infection, 16 had an infection after withdrawing acyclovir prophylaxis within a median of 49 days (range, 11 days–5.8 months). Thirty‐five percent of the VZV infected patients were hospitalized, 9% had a visceral dissemination, and 9% had postherpetic neuralgia. In multivariate analysis, higher VZV infection rate was associated with conditioning regimen with total body irradiation, immunoglobulin substitution, and antithymocyte globulin. The incidence of VZV infection increased significantly when patients had a CD4+ lymphocytes count below 23% (cHR 3.28 [95% CI, 1.09–9.81]; p = 0.03) or a CD4+/CD8+ ratio less than 0.9 (cHR 3.13 [95% CI, 1.04–9.36]; p = 0.04) at the time of stopping acyclovir prophylaxis.ConclusionAfter cessation of acyclovir prophylaxis, VZV reactivation can occur and be responsible for morbidity after allogeneic HSCT. This study suggests that the proportion of CD4+ lymphocytes and the CD4+/CD8+ ratio can inform decisions about the duration of acyclovir prophylaxis after allogeneic HSCT to prevent VZV reactivation.

show abstract

Management of a major varicella zoster exposure in a pediatric oncology population

Rossetto,

Sepkowitz,

Ackerman

et al. 2024

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

Assessing and restoring adaptive immunity to HSV, VZV, and HHV-6 in solid organ and hematopoietic cell transplant recipients

Cited by 5 publications

References 57 publications

Enhancing Efficacy and Quality of Life in Patients with Herpes Zoster Infection in Hairy Cell Leukemia

Enhancing Efficacy and Quality of Life in Patients with Herpes Zoster Infection in Hairy Cell Leukemia

VZV Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation in Children: When to Stop?

Management of a major varicella zoster exposure in a pediatric oncology population

Contact Info

Product

Resources

About